Clinical trial • Not applicable • Other

ROPIVACAINE HYDROCHLORIDE for Periacetabular osteotomy

Not applicable trial of ROPIVACAINE HYDROCHLORIDE for Periacetabular osteotomy.

Overview

Trial Therapeutic Area
Other
Trial Disease
Periacetabular osteotomy
Trial Stage
Not applicable
Drug Modality
Small molecule|Other

Key dates

Initial CTIS Submission Date
30-04-2024
First CTIS Authorization Date
25-06-2024

Trial design

Randomised, ropivacaine kabi 5 mg/ml solution for injetion (active) — perineural use; max total dose 100 mg (dose schedule not further specified). comparator: saline (placebo) — perineural use; max total volume 20 ml.-controlled Not applicable trial across 1 site in Denmark.

Randomised
Yes
Comparator
Ropivacaine Kabi 5 mg/ml solution for injetion (active) — perineural use; max total dose 100 mg (dose schedule not further specified). Comparator: SALINE (placebo) — perineural use; max total volume 20 ml.
Target Sample Size
90
Trial Duration For Participant
1

Eligibility

Recruits 90 Only adults (Patients ≥ 18 years old). Informed consent required. Vulnerable population not selected. No assent or minor consent procedures described..

Vulnerable Population
Only adults (Patients ≥ 18 years old). Informed consent required. Vulnerable population not selected. No assent or minor consent procedures described.

Inclusion criteria

  • {"criterion_text":"- Patients ≥ 18 years old\n- Informed consent\n- Scheduled for periacetabular osteotomy under general anesthesia with intubation\n- American Society of Anesthesiologists (ASA) physical status classification I to III\n- Can read and understand Danish"}

Exclusion criteria

  • {"criterion_text":"- Known allergy to ropivacaine\n- Daily use of opioids, gabapentin or tricyclic antidepressant (regardless of dose) within the last four weeks prior to surgery\n- Contraindications to Celocoxib, NSAIDs or paracetamol"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Area under curve (AUC) of pain reported on a numeric rating scale (NRS) from 0 to 10 during the first 24 hours postoperatively","definition_or_measurement_approach":"Pain reported on a numeric rating scale (NRS) from 0 to 10; AUC calculated during the first 24 hours postoperatively"}

Secondary endpoints

  • {"endpoint_text":"- The number of patients reporting moderate to severe pain at rest [>3 out of 10 on a numeric rating scale (NRS) from 0 to 10] at any point in the immediate postoperative phase (from arrival at the PACU until transfer to the ward). NRS will be assessed upon arrival at the PACU and each 30 minutes.","definition_or_measurement_approach":"NRS assessed upon arrival at the PACU and every 30 minutes; count of patients reporting NRS >3 at any point in immediate postoperative phase (arrival at PACU until transfer to ward)"}
  • {"endpoint_text":"- Pain during during mobilization (from laying down in bed till standing on the floor) assessed on a NRS at 5 hours after extubation","definition_or_measurement_approach":"NRS assessment at 5 hours after extubation during mobilization (from lying in bed until standing and walking 5 meters)"}
  • {"endpoint_text":"- Opioid use from tracheal extubation until 24 hours postoperatively","definition_or_measurement_approach":"Measurement of opioid consumption from tracheal extubation until 24 hours postoperatively"}

Recruitment

Planned Sample Size
90
Recruitment Window Months
30
Consent Approach
Informed consent required from participants. Participants must be ≥18 years old and able to read and understand Danish. No assent or minor consent procedures described. Contact for study/public and scientific queries: Matias Vested (matias.vested@regionh.dk).

Geography

Total Number Of Sites
1
Total Number Of Participants
90

Denmark

Earliest CTIS Part Ii Submission Date
05-06-2024
Latest Decision Or Authorization Date
25-06-2024
Processing Time Days
20
Number Of Sites
1
Number Of Participants
90

Sites

Site Name
Rigshospitalet
Department Name
Anaesthesia HOC
Principal Investigator Name
Matias Vested
Principal Investigator Email
matias.vested@regionh.dk
Contact Person Name
Matias Vested
Contact Person Email
matias.vested@regionh.dk
Number Of Participants
90

Sponsor

Primary sponsor

Full Name
Rigshospitalet
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Denmark

Third parties

  • {"country":"Denmark","full_name":"GCP-enheden ved Københavns Universitetshospital","duties_or_roles":"Sponsor duties code: 1","organisation_type":"Health care"}

Investigational products

Investigational Product Name
Ropivacaine Kabi 5 mg/ml solution for injetion
Active Substance
ROPIVACAINE HYDROCHLORIDE
Modality
Small molecule
Routes Of Administration
PERINEURAL USE
Route
PERINEURAL USE
Authorisation Status
Authorised (marketing authorisation MA1123/03103)
Maximum Dose
100 mg
Investigational Product Name
SALINE
Active Substance
SALINE
Modality
Other
Routes Of Administration
PERINEURAL USE
Route
PERINEURAL USE
Authorisation Status
No marketing authorisation (placebo/unlicensed)
Maximum Dose
20 ml

Related trials

Other published trials that may interest you.